GMK-HINGE FEMORAL COMPONENT SIZE 3 R
Report
- Report Number
- 3005180920-2022-00571
- Event Type
- Injury
- Date Received
- July 25, 2022
- Date of Event
- July 5, 2022
- Report Date
- July 25, 2022
- Manufacturer
- MEDACTA INTERNATIONAL SA
- Product Code
- KRO
- UDI-DI
- 07630030825446
- PMA / PMN Number
- K130299
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- US
- Reporter Occupation
- 003
Narratives
BATCH REVIEW PERFORMED ON (B)(6) 2022, LOT 189374: LOT 189374: 20 ITEMS MANUFACTURED AND RELEASED ON 25-APR-2019. EXPIRATION DATE: 2024-FEB-19. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, ALL ITEMS OF THE SAME LOT HAVE BEEN SOLD WITH 1 SIMILAR REPORTED EVENT DURING THE PERIOD OF REVIEW. ADDITIONAL IMPLANTED COMPONENTS: BATCH REVIEW PERFORMED ON 11 JULY 2022 GMK-HINGE 02.09.0220UCH UC FIXED TIBIAL INSERT SIZE 2/20MM (K172347) LOT. 183630: LOT 183630: 11 ITEMS MANUFACTURED AND RELEASED ON 21-AUG-2018. EXPIRATION DATE: 2023-JUL.24. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, 6 ITEMS OF THE SAME LOT HAVE BEEN SOLD WITH 3 SIMILAR REPORTED EVENTS DURING THE PERIOD OF REVIEW. BATCH REVIEW PERFORMED ON 11 JULY 2022 GMK-HINGE 02.09.4002R FIXED TIBIAL TRAY SIZE 2 R (K130299) LOT. 189378: LOT 189378: 24 ITEMS MANUFACTURED AND RELEASED ON 14-DEC-2018. EXPIRATION DATE: 2023-DEC-04. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, 23 ITEMS OF THE SAME LOT HAVE BEEN SOLD WITH NO SIMILAR REPORTED EVENT DURING THE PERIOD OF REVIEW.
THE PATIENT CAME IN DUE TO SIGNS OF AN INFECTION AND THE PATHOGEN IS UNKNOWN. AT 3 YEARS AND 2 MONTHS AFTER THE PRIMARY SURGERY, THE SURGEON PERFORMED A WASHOUT, REMOVED ALL COMPONENTS, AND FUSED THE PATIENT'S KNEE. THE SURGERY WAS COMPLETED SUCCESSFULLY.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 96964 | GMK-HINGE FEMORAL COMPONENT SIZE 3 R | KNEE FEMORAL COMPONENT | KRO | MEDACTA INTERNATIONAL SA | 02.09.2603R | 189374 | 07630030825446 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Female | Required Intervention |